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Summary: In the context of diagnostic procedures for congenital hyperammonaemias a method is described for the
detefmination of N-acetylglutamate synthetase in human liver tissue homogenates. The method uses [14C-U]glutamate
and acetyl CoA äs Substrates. The reaction product, N-acetylglutamate is separated from the Substrate L-glutamate by
chromatography on Extrelut . In a subsequent step on ITLC-SG ready plates N-acetylglutamate is separated from
other labeled metabolites such äs Krebs cycle intermediates. The recovery of N-acetylglutamate was 97.8%.
The precision within run and between days was 8.5% (CV) and 9.6% (CV) respectively. Reference values were estab-
lished for adult human liver.
N-Acetylglutamat Synthetase: Bestimmung des Enzyms in der menschlichen Leber
Zusammenfassung: Es wird eine Methode zur Bestimmung der N-Acetylglutamat Synthetase in Homogenaten der
menschlichen Leber beschrieben. Die Substrate sind [V*C-U]Glutamat und Acetyl CoA. Das Reaktionsprodukt,
N-Acetylglutamat, wird von£-Glutamat durch Chromatographie auf Extrelut abgetrennt. Im nachfolgenden Schritt
wird N-Acetylglutamat mittels Dünnschichtchromatographie auf Silicagel-Folien von anderen markierten Metaboliten,
namentlich aus dem Krebs-Zyi±is, abgetrennt. Die Wiederfindung von N-Acetylglutamat beträgt 97,8%.
Die Präzision in Serie und von Tag zu Tag zeigt einen Variationskoeffizienten von 8,5% resp. 9,6%. Für die menschliche
Erwachsenenleber würden Referenzwerte aufgestellt.
Introduction arginine was first shown in rat and mice liver mito-
Congenital deficiencies have been described for every chondria ** Shigesada & Tatlbana (7' 8)'
enzymatic step in the urea cycle (1^3). Since no gtudie$ Qn human liver hav(? been repOrted
An enzyme which is not directly involved in the ureä so fär, the enzyme was purified and characterized (9).
qycle,, but plays a key role in its regulatiori, is N-acetylv
glütamate synthetase (EC 2.3.1.1). It is activated by We recently had the opportunity to observe the first
arginine and catalyses the synthesis of N-acetylgluta- patient with N-acetylglutamate synthetase deficiency
mate, a physiological, potent activator of cärbamyl- (10). To confirm the diagnosis N-acetylglutamate
Phosphate synthetase (4, 5). It is present in mitochondria synthetase was determined in a liver biopsy specimen.
of liver and small intestine (6). The method presented here allows the determination
of the enzyme in liver homogenate corresponding to
The synthesis of N-acetylglutamate in mammals äs well about 30 mg of tissue. It is based on the animal experi-
as the activation of N-acetylglutamate synthetase by mmt ofShigesada & Tatibana (7, 8,11).
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After incubation the reaction product N-acetylglutamate
is separated by two Chromatographie Steps from the
remaining Substrate and other labeled metabolites.
Stop solution
160 mg N-acetylglutamate are dissolved in 10 ml H2O. Shortly
before use this solution is mixed with HC15 mol/1 in equal parts.
Substrate solution
Z-[14C-U]glutamic acid is purified on Dowex'sO WX 8 (H+form),
8.5 ml fractions being eluted with HCI (2 mol/1). The fractions
with the highest ladioactivity are pooled, dried and dissolved
in an appiopriate volume of bidistilled water to obtain a solution
with 6.7 · 1011 Bq/1. This solution is also used äs a Standard.
L-glutamic acid/L-[l*C-U\glutamic acid (80 mmol/l)
235.4 mg Z-glutamic acid are dissolved in 10 ml Tns-EDTA-
buffer. One pari of this solution (125 ) is diluted l :~2 with
L-[ 14CJglutamate immediately before use.
L-arginine (8 mmol/l)
16.9 mg I-arginine HCI are dissolved in 10 ml Tris^EDTA -buffer.
Materials and Methods
Chemicals
S-Acetyl-coenzyme-A (sodium sah) (Sigma, St. Louis, USA)
(90-95%),
L-Glutamic acid p.a. (Merck, Darmstadt, D),
Z,-[14C-U]Glutamic acid (New England Nuclear, Boston, USA)
(> 8.3 - 109 Bq/mmol, 2.5 ml),
N-Acetyl-L-glutamic acid (Fluka, Buchs, CH),
,-Pyroglutamic acid (Sigma),
Hydrochloric acid (min. 37%) (Merck),
Tris-(hydroxymethyl)-arninomethane (Merck),
Titriplex III (EDTA) p.a. (Merck),
Aquasol-2 (New England Nuclear),
Ammonia solution (min. 25%) (Merck),
Bromphenol blue (water soluble) (Fluka),
L-Arginine monohydrochloride, puriss. p.a. (Fluka).
Materials
Extrelut® (Merck),
ITLC-SG ready plates, 20 X 20 cm (Gelman Instrument Com-
pany, Ann Arbor, USA),
Dowex 50 WX 8 (Serva, Heidelberg, D).
Solutions
Ammonia 0.02 mol/1,
Tris-buffer (250 mmoi/1), EDTA (3 mmol/l), pH 8.7.
Solventsfor chromatography
A: Methanol (30 ml/l) and formic acid (12 ml/l) in Chloroform,
B: Tert. amyl alcohol (300 ml/l) in Chloroform,
C: Ether (366 ml/l) and formic acid (24 ml/l) in petroleum
et her.
Bromphenol blue
400 mg bromphenol blue are dissolved in a mixture of 2 ml
ethanol and 2 ml H2O. The pH is adjusted with 0.1 mol/1
NaOH to 6.5-7. The solution is made up to 500 ml with
ethanol 960 ml/l.
A cetyl-CoA /arginine solu tion
6 mg of acetyl-CoA are weighed intö Eppendorf tubes and 125
Tris-EDTA-buffer and 125 of arginine solution (8 mmol/l) are
added.
Procedure
Preparation of the homogenate *
Approx. 30 mg of liver tissue are homogenized in 0.5 ml of cold
bidistilled water. The homogenate is sonicated S times 5 s at
40 W (Sonifier B12, Bränson Sonic Power Comp., Danburg,
USA) under efficient cooling in ice. 0.3 ml are transferred to
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Centrifuge the tubes at 50 000 g for 10 min.
l ml of supernatant is appüed on an Extrelut® column (0.55 g
Extrelut®/column, 20 cm X l cm <jt).
The column is eluted with 50 ml tert. amyl alcohol (300 ml/l)
in Chloroform (solvent B). The whple eluate is then eväpöirated
under nitrogen in a waterbath (50 °C). The residue is diluted
in 100 ammoniä solution (0.02 mol/1).
For further Chromatographie Separation 10 of the dissolved
residue are put on ITLC-SG plates. The plate is chiom&o-
graphed in solvent A (front up to 20 cm), then dried 10 min
at 100 °C. For the second dimension chromatography is done
pver a 10 cm distance with solvent C (approx. 10 min) and then
dried again. For detection the plate is sprayed with bromphenol
blue.
The «Nracetylglutamate spots (Rf: 0.3/0.05) are cut put and placed
in a counting vial. 5 ml ammoniä (0.02 mol/1) are added, the vial
shaken for 10 min and' then 7 ml aquaspl-ä js added. The solution
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is mixed and counted for 10 min in beta counter (Mod. Inter-
technique, Paris, France).
The final concentration in the enzyme assay is:
Giutamic acid 20 mmol/1,
Acetyl CoA 7 mmol/1,
L-arginine l mol/1.
The enzyme activity is expressed in m U · g'1 liver tissue (wet
weight), calculated according to the following formula:
Bq NAG · nmol glu - Fc - Fv - Ft
Bqst
(NAG = N-acetylglutamate, glu - glutamic acid, Fc = dilution
factor for chromatography, Fv = dilution factor for homo-
genate, Ft = time factor, st = glu tamic acid Standard).
particularly of N-acetylglutamate, the product of the
enzyme reaction.
Recovery of N-acetylglutamate
These experiments had to be done with radioactive
N-acetylglutamate, since this final reaction product
becomes labeled during its synthesis by N-acetyl-
glutamate synthetase. For this purpose [14C]-
N-acetylglutarnate was synthesized from [14C]-
L-glutamate according to a modification of the method
ofNoyori (12).
Results
Separation of Substrates and products
Column chromatography on Extrelut
We tried to separate Z-glutamate, N-acetylglutamate and
/,-pyroglutamate (arising from glutamate) on Extrelut
0.5 ml of a solution containing l mg each of L-gJuta-
mate, N-acetylglutamate and L-pyroglutamate was
mixed with 0.5 rnl HC1 (l mol/1). The mixture was put on
the Extrelut® column (0.55 g Extrelut®, column
20 cm X l cm ̂ ). The column was eluted with 20 ml
of solvent B. The eluate was collected äs a whole or in
5 ml fractions which were theri pooled. The whole
eluate and the fractions were dried at 50 °C under nitro-
gen and the residüe taken up in l ml ammonia (0.02
mol/1). 10 of these Solutions were put on a cellulose
thin layer plate (Merck). N-acetylglutamate andL-pyro-
glutamate are eluted tögether cornpletely. Glutamate
however is retained. Examination of the different
eluted fractions did not reveal any ehänges in Separation
compared to the batqh elution.
Thin layer chromatography
If enzyme analysis is performed on tissue samples, inter-
fering metabolites are to be expected. These must be
separated from the Substrate and product of the reaction.
Particularly metabolites from the Krebs cycle which may
interfere are not separated by the Extrelut® step. There-
fore a thiri layer chromatography step was added. After
trying several Systems, a fully satisfactpry method was
found1 using a 2-dimensional chrprnatography on ITLC-
SG^-ready plates (using solvente A and C äs indicated).
Bromphenol blue was used for the detection. Figure l
shows the Separation of succinate,L-pyrogjiutaniate,
2-oxogJutarate, N-acetylglutamate, L^-malate, L-citrate
and L-glutamate.
(D*
On the bäsis of these findings it was possible to com-
bine the Extrelut^ step with a thin layer chrorhato-
graphy step. However, it was necessary to assess the
reeovery of the substances separated in these two Steps,








Solvents: 1: Methanol (30 ml/l) and formic acid (12 ml/l)
in Chloroform,
2: Ether (36.6 ml/1) and formic acid (24 ml/l) in
petroleum ether.
* labeled compounds (see text).
10 ml of HC1 solution (0.5 mol/1) containing [14C]£-
acetylglutamate (83 kBq/1) and N-acetylglutamate
(l g/l) was prepared. l ml of this solution was put on
10 different Extrelut® columns and eluted äs described
above. The evaporated eluate was dissolved in ammonia
(0.02 mol/1). 50 were put in aquasol-2 and the radio-
aetivity counted. A further 20 of eluate were put on
10 different Extrelut columns and eluted äs described
above. The evaporated eluate was dissolved in ammonia
(0.02 mol/1). 50 were put in aquasol-2 and the radio-
activity counted. A further 20 of eluate were put on
the ITLC-SG-ready plates and chromatographed äs
described above. The N-acetylglutamate spot was cut out
and counted. The recovery after the Extrelut" step alone
and after Extrelut® elution and ITLC-SG-chromato-
graphy was calculated in relation to the amount of
[14C]N-acetylglutamate applied originally.
J, Cün. Chem. Qin. Biochem. / Vol. 20,1982 / No. 5
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The recovery for the Extrelut® step was 99.8% (CV
0.5%, n = 10). For the Extrelut® System with the suc-
ceeding Chromatographie step the recovery was 97.8%
(CV 1.3%, n = 10). These very high recoveries prove
that the condition chosen for both Steps are correct.
These recoveries are higher than those described by
Shigesada & Tatibana in their System (13).
Testing the enzyme assay by autoradiography
[14C]N-acetylglutamate synthesized during iiicubation
with liver homogenate can also be demonstrated using
autoradiographic techniques. After the 2-dimensional
chromatography on ITLS-SG ready plates these were
placed directiy on x-ray screen film (NS 2T, Kodak)..
After three days exposure the films were develpped
according to Swanstrom &Shank (14). With this method
activities up to 0.8 Bq/cm2 can be detected.
Figure l shows that during the incubation new meta^
bolites (*) arise from the [14C]glutamate. These metab-
olites can easily^be separated by the thin layer step
(ITLC-SG-system) from the Substrate L-glutamate and
the product N-acetylglutamate.
Further investigations of the enzyme reaction
Velocity and pH
The dependency of the velocity of the enzyme reaction
on the amount of tissue used in the assay exhibited
linearity up to a tissue content of 10 mg per assay.
With respect to the incubation time the reaction is linear
up to 20 minutes.
The dependency of the reaction on the pH is shown in
figure 2. With and without activation of the enzyme by
arginine, the pH Optimum is around 8.5. The activation
due to arginine approx. doubles the activity. Further




7.5 ao as 9.0
pH
9:5
acetylglutamate synthetase preparation (9). The Km
values for //-glutamic acid and acetyl CoA were 8.1
mmol/1 and 4.4 mmol/1 respectively.
Within-run precision: Using the same tissue sample the
within-ruii precision showed a coefficjent of Variation
of 8.7% at a mean activity of 30.7 mU/g tissue (n = 6).
This is in oür opiniori acceptable in view of the com-
plexity of the enzyme assay;
Between däy precision: The precisipn from day to day
shows a coefficient of Variation of 9.6% (tab. 1). The
data further indicate that the störage of the liver
homogenate at — 20 °C during 5 days does not lead to
a decrease of enzyme activity.
Tab. 1. N-Acetylglutamate synthetase: BetweerHiay precisiönj
Enzyme, activity measured on the same tissue sample at
5 subsequent days.
Number Time of störage N-acetylglutamate synthetase
















= 30.8, s = 2.9, CV = 9.<
Fig. 2. N-Acetylglutamate synthetase.
Dependency of the enzyme reaction on pH.
Reference values
The amount of liver tissue (about 30 rng) necessäry for
the assay of N-äcetylglutämäte synthetase usually
cannot be obtained by a needle biopsy. Multiple needle
biopsies embody the risk of haemorrhage; thus it is
preferable to perform a surgical 'biopsy. TTiis becqmes
a limiting factor for establishing reference values. There^
fore orily a smäll number öf liver specimens could be
examined. Most of the control biopsies were taken from
patients who were operated becraise of adenocarcinomä
of the colon or rectum. Due to the limited number of
assays, we could not account for sex differenees. The
age of the patients varied between 48 arid 64 years. Pre-
operätively the patients had a standardized diet coii-
sistiiig of bouillon and tea for two days. A protein effect
leading to an activation of N-acetylglutamate synthetase
which is known for other enzymes of the urea cycle can
be avoided with this diet (15-17).
The determination of N-acetylglutamate S5m1hetase is
merely used in the context öf diagnoses of hyperammon-
aemia in the newborn and infant age. It wasrhpwever not
possible for ethical reasons to get reference samples in
this age periöd. Table 2 shows the reference values with
and without arginine per g liver weight and per mg protein
in 12 ädult patients.
If this enzyme determination is done for diagnostie
pufjposes an assay with and without Arginine must be
j. Öin. Chem. Clin. Biochem. / Vol. 20,1982 / No. 5
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performed to guarantee a füll activation of the enzyme
and to detect also enzyme variants which may be activ-
ated in a different way.
Tab. 2. Reference values of N-acetylglutamate synthetase in adult





mU · g"1 liver
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The purpose of setting up a method for the determination
of N-acetylglutamate synthetase in human liver biopsy
specimens is mainly airned at the diagnosis of congenital
hyperammonaemias (1—3).
N-acetylglutamate generated in the N-acetylglutamate
synthetase reaction (18, 19) holds a key position in
regulation of urea synthesis. As shown recently, the
deficiency of N-acetylglutamate synthetase rnay have
been the cause of hyperammonaemia of unknown origin
in newborn and small infants (10).
The methods for the determination of most urea cycle
enzymes are not easy to perform. This is also the case for
N-acetylglutamate synthetase.
The method described uses [14C-U]labeled ghitamate
ahd acetyl CoA äs Substrates. The Substrate concentra-
tions used are based oii kinetic studies with the purified
human enzyme (9). It is composed of three Steps: the
iricubation step and two Separation Steps. After incuba*
tion the reaction product N-acetylglutamate is separated
from the Substrate L-glutamate by chromatography on
Extrelut® instead of Dowex 50-X8, äs proposed by
Shigesada & Tatibana (8). Many side reactions are to be
expected in crude liver biopsy homogenates. Therefore
a newly introduced thin layer chromatography step is
used to separate the reaction product from the labeled
metabolites, particularly from the Krebs cycle inter-
mediates. Although some of these could be avoided by
using glutamate labeled in position l, this compound
is only available äs the J9.Z,-racemate and with a con-
siderably lower specific activity.
Working with sonicated liver homogenates the activity
of aminoacylase (EC 3.5.1.14) could be a disturbing
factor, leading t o the breakdown of N-acetylglutamate.
According to Reglero et al. (20) there is practically no
activity of this enzyme in the mitochondria, whereas
it is easily measurable in the cytosol (21). However
aminoacylase exhibits its pH Optimum at pH 7 (22).
At pH 8.5 used in the N-acetylglutamate synthetase
reaction the activity of the aminoacylase is approxi-
rnately half the maximal rate (23). The final concen-
tration of N-acetylglutarnate in the assay described
is below 0.1 mmol/1, whereas the Km value of amino-
acylase for N-acetylglutamate is about 10 mmol/1 (20).
On the basis of these observations we think that the
interference of aminoacylase, if present at all, is certainly
minimal.
The method has a good within-run and between day
precision äs well äs a good recovery. The enzyme
activity is linear with time and protein content over a .
large ränge.
Its usefullness has been proven in the diagnosis of the
first case of N-acetylglutamate synthetase deficiency
(10)-,
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